Canaccord Genuity Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Underappreciated Cumulative Value for GATTEX, NATPARA, and Sensipar Royalty
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Price: $45.97 --0%
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on NPS Pharmaceuticals (NASDAQ: NPSP) price target raised to $13.00.
Analyst, George Farmer, said, "Consistent with an expected FDA Standard Review timeline, NPSP’s lead asset GATTEX for treatment of short bowel syndrome received a PDUFA date of September 30. We anticipate an FDA advisory panel will convene towards mid-year to assess the GATTEX NDA. Informed by compelling efficacy and safety data from the Phase III STEPS trial, we expect a clean panel vote and successful approval. With regulatory review active, we do not expect further data update from the STEPS2 extension trial prior to an approval decision. We model for launch in late Q4/12 and US peak sales of $250M in 2019."
"We estimate 2012-end cash of $59M, based on $162M reported at 2011-end and our 2012E $101M burn, just below guided $105-125M burn. We model for a cash flow and EPS positive 2013, supported by est. $76M in GATTEX/NATPARA product sales."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals click here. For more ratings news on NPS Pharmaceuticals click here.
Shares of NPS Pharmaceuticals closed at $7.39 yesterday.
Analyst, George Farmer, said, "Consistent with an expected FDA Standard Review timeline, NPSP’s lead asset GATTEX for treatment of short bowel syndrome received a PDUFA date of September 30. We anticipate an FDA advisory panel will convene towards mid-year to assess the GATTEX NDA. Informed by compelling efficacy and safety data from the Phase III STEPS trial, we expect a clean panel vote and successful approval. With regulatory review active, we do not expect further data update from the STEPS2 extension trial prior to an approval decision. We model for launch in late Q4/12 and US peak sales of $250M in 2019."
"We estimate 2012-end cash of $59M, based on $162M reported at 2011-end and our 2012E $101M burn, just below guided $105-125M burn. We model for a cash flow and EPS positive 2013, supported by est. $76M in GATTEX/NATPARA product sales."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals click here. For more ratings news on NPS Pharmaceuticals click here.
Shares of NPS Pharmaceuticals closed at $7.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- DA Davidson Starts Everus (ECG) at Buy
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
